Pharmaceuticals, Biotechnology and Life Sciences
OTX-TP failed to meet primary endpoint but achieved statisticallysignificant reduction of intraocular pressure versus placebo at eight ofthe nine pre-specified time points
Said Barry Butler, “I believe the advantages offered by theEyesol® platform will bring significant benefits to glaucomapatients.”
standalone implantation of two iStent®Trabecular Micro-Bypass Stents in newly diagnosed primary open-angleglaucoma (POAG) eyes achieved a 35.3% reduction in meanintraocular pressure (IOP) to 16.5 mmHg after five years of follow-up.
Allergan plc has completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that…